Piper Sandler analyst Matt O’Brien initiated coverage of TransMedics with an Overweight rating and $95 price target. The analyst believes the company is changing the organ transplant market with proprietary organ preservation technologies and wholly-owned transport services. TransMedics’ patented devices better preserve organs while its logistical network beats the outdated models, the analyst tells investors in a research note. The firm believes the company is building a “sizable moat around its business” with these transport services, which will “elevate its value in the coming years.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics participates in a conference call with JPMorgan
- TransMedics price target raised to $102 from $96 at Canaccord
- TransMedics price target raised to $105 from $92 at Oppenheimer
- TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results
- TransMedics sees FY24 revenue $360M-$370M, consensus $330.23M